Corcept Therapeutics Faces Securities Fraud Suit Over Disclosure Failures
Corcept Therapeutics (NASDAQ: CORT) is the target of a class action lawsuit alleging securities fraud between October 2024 and December 2025. The Rosen Law Firm is leading the litigation, which centers on claims that the company misled investors regarding its business operations and regulatory compliance. This legal challenge marks a critical period of scrutiny for the pharmaceutical firm's corporate governance and public disclosure practices.